Table 3.

 Univariate analysis of effects of prednisolone for primary and secondary outcomes

Outcome	n	p‐values for prednisolone vs. placebo in all patients and for interactions between study drug and different variables
		All patients	Age	Atopy	B‐eos	Picornavirus	Rhinovirus	Enterovirus	RSS at entry*
Time until ready for discharge, h	58	0.71	0.034	0.15	0.73	0.026	0.050	0.0002	0.20
Duration of cough, days	50	0.12	0.97	0.091	0.079	0.93	0.033	0.28	0.40
Duration of dyspnea, days	50	0.61	0.80	0.057	0.42	0.24	0.019	0.50	0.96
Outpatient visit, no.†	46	0.99	0.82	0.77	0.83	0.94	0.92	0.79	0.77
Rehospitalized, no.†	46	0.89	0.94	0.84	0.90	0.98	0.89	0.86	0.87
B‐eos at discharge, ×109/l	53	<0.0001	0.71	0.80	0.22	0.79	0.72	0.60	0.41
B‐eos 2 wk after discharge, ×109/l	52	0.24	0.45	0.91	0.33	0.76	0.24	0.74	0.51

B‐Eos, blood eosinophils.

Values are medians (interquartile range) or number of subjects (%). Analysis using multivariate regression analysis.

*Respiratory symptoms scores (RSS) were assessed on a scale from 0 (none) to 12 (severe) at study entry.

†As a result of wheezing during 2 months after discharge.